VEGF is recognized as an essential regulator of normal and abnormal blood vessel growth, and treatment with the anti-VEGF antibody bevacizumab is now a first-line therapy for metastatic colorectal cancer, although unfortunately many cases of resistance due to tumor infiltration by CD11b+Gr+ cells have been reported. Here, VEGFA is linked to metastatic colorectal cancer.